<u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier	MLH1, VENTANA, NBP2-47656;	
name, catalogue number and RRID, if available.	MSH2, VENTANA, TA347005;	
	MSH6, VENTANA, NBP2-37537;	
	PMS2, VENTANA, NBP2-46459.(page5 line130)	
Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain.		Not
Provide accession number in repository OR		applied
supplier name, catalog number, clone number,		
OR RRID		
Primary cultures: Provide species, strain, sex of		Not
origin, genetic modification status.		applied
Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age,		Not
genetic modification status. Provide accession		applied
number in repository OR supplier name, catalog		
number, clone number, OR RRID		
Animal observed in or captured from the		Not
field: Provide species, sex and age where		applied
possible		
Model organisms: Provide Accession number		Not
in repository (where relevant) OR RRID		applied
Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession	res (indicate where provided, section/ paragraph)	Not
		applied
number if available, and source (including location		applieu
for collected wild specimens)		
Microbes: provide species and strain, unique		Not
accession number if available, and source		applied
Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or	Medical Ethics Committee of Nanfang Hospital	
equivalent committee(s), provide reference number	NFEC-2017-193(page4 line 111-112)	
for approval.		
Provide statement confirming informed consent	PIC version number :2017-12-06V1.0	
obtained from study participants.		
Report on age and sex for all study participants.	Age: 49, 57, 66, 75, 61, 42; Sex: M, M, F, F, M, M.	
	-	
	Se(page6 line 170-174)	

<u>Design</u>

Study protocol	Yes (indicate where provided:	n/a
For clinical trials, provide the trial registration		Not applied
number OR cite DOI in manuscript.		
Laboratory protocol	Yes (indicate where provided:	n/a
Provide DOI or other citation details if detailed step-	· · · ·	Not applied
by-step protocols are available.		
Experimental study design (statistics details)	Yes (indicate where provided:	n/a
State whether and how the following have been		
done , or if they were not carried out.		
Sample size determination	We only chose 6 patients.(page4 line103- 105)	
Randomisation		Not applied
Blinding		Not applied
Inclusion/exclusion criteria		Not applied
Sample definition and in-laboratory replication	Yes (indicate where provided:	n/a
State number of times the experiment was replicated in laboratory		Not applied
Define whether data describe technical or biological replicates		Not applied
Ethics	Yes (indicate where provided:	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	AF/SC-09/03.2	
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		Not applied
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.		Not applied
Dual Use Research of Concern (DURC)	Yes (indicate where provided:	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval		Not applied

<u>Analysis</u>

Attrition	Yes (indicate where provided:	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.		Not applied
Statistics	Yes (indicate where provided:	n/a
Describe statistical tests used and justify choice of tests.	Statistical analysis was carried out using the two-tailed Student's t-test.(page6 line164- 166)	
Data Availability	Yes (indicate where provided:	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.		Not applied
If data are publicly available, provide accession number in repository or DOI or URL.		Not applied
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.		Not applied

Code Availability	Yes (indicate where provided:	n/a
For all newly generated code and software essential		Not applied
for replicating the main findings of the study:		
State whether the code or software is available.		Not applied
If code is publicly available, provide accession		Not applied
number in repository, or DOI or URL.		

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.	

Article information: http://dx.doi.org/10.21037/tcr-20-2762